Patrick M Sweeney & Associates Inc. Reduces Stake in Haleon plc (NYSE:HLN)

Patrick M Sweeney & Associates Inc. lowered its holdings in Haleon plc (NYSE:HLN) by 27.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 70,043 shares of the company’s stock after selling 26,500 shares during the quarter. Patrick M Sweeney & Associates Inc.’s holdings in Haleon were worth $668,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Blue Trust Inc. lifted its holdings in Haleon by 19.2% in the 4th quarter. Blue Trust Inc. now owns 47,876 shares of the company’s stock worth $507,000 after buying an additional 7,703 shares during the period. Drive Wealth Management LLC purchased a new stake in Haleon in the 4th quarter worth approximately $164,000. Geneos Wealth Management Inc. purchased a new stake in Haleon in the 4th quarter worth approximately $35,000. Brighton Jones LLC purchased a new stake in Haleon in the 4th quarter worth approximately $187,000. Finally, Janney Montgomery Scott LLC lifted its holdings in Haleon by 13.3% in the 4th quarter. Janney Montgomery Scott LLC now owns 850,563 shares of the company’s stock worth $8,114,000 after buying an additional 99,666 shares during the period. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Stock Performance

Shares of HLN opened at $9.59 on Tuesday. The business’s fifty day simple moving average is $9.54 and its two-hundred day simple moving average is $9.74. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. Haleon plc has a 12 month low of $7.89 and a 12 month high of $10.80. The company has a market cap of $43.39 billion, a price-to-earnings ratio of 28.19, a P/E/G ratio of 2.60 and a beta of 0.29.

Haleon (NYSE:HLN) last issued its earnings results on Thursday, October 31st. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.11 by $0.03. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The business had revenue of $3.62 billion for the quarter, compared to the consensus estimate of $3.74 billion. During the same period last year, the business posted $0.10 EPS. Research analysts anticipate that Haleon plc will post 0.44 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. UBS Group raised Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. Morgan Stanley lowered Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Finally, Sanford C. Bernstein lowered Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Three analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Haleon currently has an average rating of “Moderate Buy” and an average price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.